Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03292406 · ClinicalTrials.gov registry record · Phase 2
A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)
A Phase 2 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT03292406 is a Phase 2 study that has completed, run by Galderma R&D. The registered enrollment target is 86 participants.
The verdict
NCT03292406, a Phase 2 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
To assess the efficacy, safety and pharmacokinetics in participants treated with CD11301 gel vs. placebo for early stage CTCL (IA, IB, or IIA).
Interventions
- DRUG Placebo
- DRUG CD11301 0.03%
- DRUG CD11301 0.06%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2017-12-19 |
| Est. Completion | 2020-03-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03292406
The ClinicalTrials.gov registry entry for NCT03292406 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03292406 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03292406 about?
NCT03292406 is a clinical study titled "A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)". To assess the efficacy, safety and pharmacokinetics in participants treated with CD11301 gel vs. placebo for early stage CTCL (IA, IB, or IIA).
What is the current status of trial NCT03292406?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2017-12-19. Estimated completion is 2020-03-17.
What interventions are being tested in trial NCT03292406?
The interventions under investigation include: Placebo (DRUG), CD11301 0.03% (DRUG), CD11301 0.06% (DRUG).
Who is sponsoring clinical trial NCT03292406?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.